Tempus AI Inc (NASDAQ:TEM) shares are trading higher by 7.45% to $35.82 during Tuesday’s session after the company announced it was granted Advanced Diagnostic Laboratory Test (ADLT) status for its next-generation sequencing assay from the Centers for Medicare & Medicaid Services. The company says this makes xT CDx the first FDA-approved sequencing assay to provide tumor mutation profiling through matched normal sequence analysis for patients with solid organ neoplasms. The ADLT status additionally confirms that xT CDx meets CMS’s criteria for providing unique clinical diagnostic information. …